From Penicillin to Trillions
Strategies, Influence, and Deviations in the Pharmaceutical Sector
Palabras clave:
Pharmaceutical Sector, Fraud, Lobbying , Marketing , Individual and public healthResumen
Manipulation, fraud, crimes, billions spent on lobbying and electoral financing, undue interference in regulatory bodies, and massive investments in marketing are recurrent strategies employed by the pharmaceutical sector to maximize profits, often at the expense of individual and public health.
Descargas
Citas
ANGELL, Marcia. The Truth about the Drug Companies: how they deceive us and what to do about it. illustrated edition (2005). New York City, NY, United States: Random House Trade, 2005. 319 p.
APPLEQUIST, Janelle; BALL, Jennifer. An Updated Analysis of Direct-to-Consumer Television Advertisements for Prescription Drugs. The Annals of Family Medicine, [S.L.], v. 16, n. 3, p. 211-216, may. 2018. http://dx.doi.org/10.1370/afm.2220.
AUSTAD, Kirsten E. et al. Medical Students' Exposure to and Attitudes about the Pharmaceutical Industry: a systematic review. Plos Medicine, [S.L.], v. 8, n. 5, p. 1001037, 24 may. 2011. http://dx.doi.org/10.1371/journal.pmed.1001037.
BEKELMAN, Justin E. et al. Scope and Impact of Financial Conflicts of Interest in Biomedical Research. Jama, [S.L.], v. 289, n. 4, p. 454, 22 jan. 2003. http://dx.doi.org/10.1001/jama.289.4.454.
BERENSON, Alex. Merck Agrees to Settle Vioxx Suits for $4.85 Billion. The New York Times. 2007. Available: https://www.nytimes.com/2007/11/09/business/09merck.html. Accessed on: 11 out. 2024.
BINDSLEV, Julie Bolette Brix et al. Underreporting of conflicts of interest in clinical practice guidelines: cross sectional study. Bmc Medical Ethics, [S.L.], v. 14, n. 1, p. 1, 3 may. 2013. http://dx.doi.org/10.1186/1472-6939-14-19.
BRENNAN, Troyen A. et al. Health Industry Practices That Create Conflicts of Interest. Jama, [S.L.], v. 295, n. 4, p. 429, 25 jan. 2006. http://dx.doi.org/10.1001/jama.295.4.429.
CAMARGO JR., Kenneth Rochel de. O grande investimento da indústria farmacêutica nos últimos anos foi para disfunção erétil, não para malária. [Entrevista concedida a Raquel Júnia]. EPSJV/Fiocruz (Escola Politécnica de Saúde Joaquim Venâncio), [Online], nov. 2016. Available: https://www.epsjv.fiocruz.br/noticias/entrevista/o-grande-investimento-da-industria-farmaceutica-nos-ultimos-anos-foi-para Accessed on: 11 oct. 2024.
CHOUDHRY, Niteesh K. et al. Relationships Between Authors of Clinical Practice Guidelines and the Pharmaceutical Industry. Jama, [S.L.], v. 287, n. 5, p. 612, 6 feb. 2002. American Medical Association (AMA). http://dx.doi.org/10.1001/jama.287.5.612.
CITELINE. Pharma Intelligence. Pharma R&D: annual review 2022. London (England): Pharma Intelligence, 2022. 55 p. Available: https://pharmaintelligence.informa.com/. Accessed on: 11 oct. 2024.
COHEN, Deborah et al. Cancer drugs: high price, uncertain value. Bmj, [S.L.], p. 4543, 4 oct. 2017. http://dx.doi.org/10.1136/bmj.j4543.
DANA, Jason; LOEWENSTEIN, George. A Social Science Perspective on Gifts to Physicians from Industry. Jama, [S.L.], v. 290, n. 2, p. 252, 9 jul. 2003. http://dx.doi.org/10.1001/jama.290.2.252.
DEJONG, Colette et al. Pharmaceutical Industry–Sponsored Meals and Physician Prescribing Patterns for Medicare Beneficiaries. Jama Internal Medicine, [S.L.], v. 176, n. 8, p. 1114, 1 aug. 2016. http://dx.doi.org/10.1001/jamainternmed.2016.2765.
DJULBEGOVIC, Benjamin et al. The uncertainty principle and industry sponsored research. The Lancet, [S.L.], v. 356, n. 9230, p. 635 638, aug. 2000. http://dx.doi.org/10.1016/S0140-6736(00)02605-2.
FACHER, Lev. Pharma funded more than 2,400 state lawmaker campaigns in 2020, new STAT analysis finds. STAT. Boston, MA, U.S. jun. 2021. Available: https://www.statnews.com/feature/prescription-politics/state-full-data-set/. Accessed on: 11 oct. 2024.
FLACCO, Maria Elena et al. Head-to-head randomized trials are mostly industry sponsored and almost always favor the industry sponsor. Journal Of Clinical Epidemiology, [S.L.], v. 68, n. 7, p. 811-820, jul. 2015. http://dx.doi.org/10.1016/j.jclinepi.2014.12.016
FOJO, Tito et al. Unintended Consequences of Expensive Cancer Therapeutics - The Pursuit of Marginal Indications and a Me-Too Mentality That Stifles Innovation and Creativity. Jama Otolaryngology-Head & Neck Surgery, [S.L.], v. 140, n. 12, p. 1225, 1 dec. 2014. http://dx.doi.org/10.1001/jamaoto.2014.1570.
FRESQUES, Hannah. Doctors Prescribe More of a Drug If They Receive Money from a Pharma Company Tied to It. ProPublica: Dollars for Doctors. 2019. Available: https://www.propublica.org/article/doctors-prescribe-more-of-a-drug-if-they-receive-money-from-a-pharma-company-tied-to-it. Accessed on: 11 oct. 2024.
GLOY, Viktoria et al. The evidence base of US Food and Drug Administration approvals of novel cancer therapies from 2000 to 2020. International Journal of Cancer, [S.L.], v. 152, n. 12, p. 2474-2484, 24 feb. 2023. http://dx.doi.org/10.1002/ijc.34473.
HARRIS, Gardiner; BERENSON, Alex. 10 Voters on Panel Backing Pain Pills Had Industry Ties. The New York Times. 2005. Available: https://www.nytimes.com/2005/02/25/politics/10-voters-on-panel-backing-pain-pills-had-industry-ties.html. Accessed on: 11 oct. 2024.
HAYES, Michael J.; PRASAD, Vinay. Financial Conflicts of Interest at FDA Drug Advisory Committee Meetings. Hastings Center Report, [S.L.], v. 48, n. 2, p. 10 13, mar. 2018. Wiley. http://dx.doi.org/10.1002/hast.833.
HIGHAM, Scott; BERNSTEIN, Lenny. The Drug Industry’s Triumph over the DEA. The Washington Post. Washington, D.C., U.S. oct. 2017. Available: https://www.washingtonpost.com/graphics/2017/investigations/dea-drug-industry-congress/. Accessed on: 11 oct. 2024.
HOTEZ, Peter J et al. Rescuing the bottom billion through control of neglected tropical diseases. The Lancet, [S.L.], v. 373, n. 9674, p. 1570-1575, may. 2009. http://dx.doi.org/10.1016/s0140-6736(09)60233-6.
KATZ, Dana et al. All Gifts Large and Small. The American Journal of Bioethics, [S.L.], v. 3, n. 3, p. 39-46, aug. 2003. http://dx.doi.org/10.1162/15265160360706552.
KNIGHT, Victoria et al. Pharma Campaign Cash Delivered to Key Lawmakers with Surgical Precision. KFF Health News. oct. 2021. Available: https://kffhealthnews.org/news/article/pharma-campaign-cash-delivered-to-key-lawmakers-with-surgical-precision/. Accessed on: 11 oct. 2024.
KOPP, Emily et al.KFF Health News. 2018. Patient Advocacy Groups Take in Millions From Drugmakers. Is There a Payback? Available: https://kffhealthnews.org/news/patient-advocacy-groups-take-in-millions-from-drugmakers-is-there-a-payback/. Accessed on: 11 oct. 2024.
LEE, Mina et al. Factors Influencing Consumers' Attitudinal and Behavioral Responses to Direct-To-Consumer and Over-the-Counter Drug Advertising. Journal of Health Communication, [S.L.], v. 20, n. 4, p. 431-444, 2 mar. 2015. http://dx.doi.org/10.1080/10810730.2014.965367.
LEXCHIN, J. et al. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. Bmj, [S.L.], v. 326, n. 7400, p. 1167, may. 2003. http://dx.doi.org/10.1136/bmj.326.7400.1167.
LEXCHIN, Joel et al. National patient groups in Canada and their disclosure of relationships with pharmaceutical companies: a cross-sectional study. Bmj Open, [S.L.], v. 12, n. 3, p. 055287, mar. 2022. http://dx.doi.org/10.1136/bmjopen-2021-055287.
LEXCHIN, Joel. Those Who Have the Gold Make the Evidence: how the pharmaceutical industry biases the outcomes of clinical trials of medications. Science And Engineering Ethics, [S.L.], v. 18, n. 2, p. 247-261, 15 feb. 2011. http://dx.doi.org/10.1007/s11948-011-9265-3.
LIGHT, Donald. W.; LEXCHIN, Joel. R. Pharmaceutical research and development: what do we get for all that money?. Bmj, [S.L.], v. 345, n. 071, p. 1-5, 7 aug. 2012. http://dx.doi.org/10.1136/bmj.e4348.
LUNDH, Andreas et al. Industry sponsorship and research outcome: systematic review with meta-analysis. Intensive Care Medicine, [S.L.], v. 44, n. 10, p. 1603-1612, 21 aug. 2018. http://dx.doi.org/10.1007/s00134-018-5293-7.
LURIE, Peter et al. Financial Conflict of Interest Disclosure and Voting Patterns at Food and Drug Administration Drug Advisory Committee Meetings. Jama, [S.L.], v. 295, n. 16, p. 1921, 26 apr. 2006. http://dx.doi.org/10.1001/jama.295.16.1921.
MCCOY, Matthew S. et al. Conflicts of Interest for Patient-Advocacy Organizations. New England Journal of Medicine, [S.L.], v. 376, n. 9, p. 880, mar. 2017. http://dx.doi.org/10.1056/nejmsr1610625.
MCHENRY, Leemon. of Sophists and Spin-Doctors: industry-sponsored ghostwriting and the crisis of academic medicine. Mens Sana Monographs, [S.L.], v. 8, n. 1, p. 129, 2010. http://dx.doi.org/10.4103/0973-1229.58824.
MITCHELL, Aaron P. et al. Financial Relationships with Industry Among National Comprehensive Cancer Network Guideline Authors. Jama Oncology, [S.L.], v. 2, n. 12, p. 1628, 1 dec. 2016. http://dx.doi.org/10.1001/jamaoncol.2016.2710.
MOFFATT, Barton; ELLIOTT, Carl. Ghost Marketing: pharmaceutical companies and ghostwritten journal articles. Perspectives in Biology and Medicine, [S.L.], v. 50, n. 1, p. 18-31, dec. 2007. http://dx.doi.org/10.1353/pbm.2007.0009.
MORGAN, Steven et al. “Breakthrough” drugs and growth in expenditure on prescription drugs in Canada. Bmj, [S.L.], v. 331, n. 7520, p. 815, sep. 2005. http://dx.doi.org/10.1136/bmj.38582.703866.ae.
MOTOLA, Domenico et al. An update on the first decade of the European centralized procedure: how many innovative drugs?. British Journal of Clinical Pharmacology, [S.L.], v. 62, n. 5, p. 610-616, 23 jun. 2006. http://dx.doi.org/10.1111/j.1365-2125.2006.02700.x.
MOYNIHAN, R. Who pays for the pizza? Redefining the relationships between doctors and drug companies. 1. Bmj, [S.L.], v. 326, n. 7400, p. 1189, 2003. http://dx.doi.org/10.1136/bmj.326.7400.1189.
MUKHERJEE, Debabrata et al. Risk of Cardiovascular Events Associated with Selective COX 2 Inhibitors. Jama, [S.L.], v. 286, n. 8, p. 954, 22 aug. 2001. http://dx.doi.org/10.1001/jama.286.8.954.
MULINARI, Shai et al. Five years of pharmaceutical industry funding of patient organisations in Sweden: cross-sectional study of companies, patient organisations and drugs. Plos One, [S.L.], v. 15, n. 6, p. 0235021, 24 jun. 2020. http://dx.doi.org/10.1371/journal.pone.0235021.
NACI, Huseyin et al. Why the drug development pipeline is not delivering better medicines. Bmj, [S.L.], p. 5542, 23 oct. 2015. http://dx.doi.org/10.1136/bmj.h5542.
NEJSTGAARD, Camilla H et al. Association between conflicts of interest and favourable recommendations in clinical guidelines, advisory committee reports, opinion pieces, and narrative reviews: systematic review. Bmj, [S.L.], p. 1-12, 9 dec. 2020. http://dx.doi.org/10.1136/bmj.m4234.
NEUMAN, J. et al. Prevalence of financial conflicts of interest among panel members producing clinical practice guidelines in Canada and United States: cross sectional study. Bmj, [S.L.], v. 343, n. 112, p. 5621, 11 oct. 2011. http://dx.doi.org/10.1136/bmj.d5621.
NYT - The New York Times. Experts and the Drug Industry. Opinion: Editorial. 2005. Available: https://www.nytimes.com/2005/03/04/opinion/experts-and-the-drug-industry.html. Acesso em: 11 out. 2024.
OPEN PAYMENTS - The Open Payments Search Tool. National Transparency Program. Centers for Medicare & Medicaid Services (CMS). Baltimore, MD; U.S. 2024. Available: https://openpaymentsdata.cms.gov/. Accessed on: 11 oct. 2024.
OPENSECRETS - The nation's premier research group tracking money in U.S. politics. 2024. Washington, D.C., U.S. Available: https://www.opensecrets.org/. Accessed on: 11 oct. 2024.
ORLOWSKI, James P.; WATESKA, Leon. The Effects of Pharmaceutical Firm Enticements on Physician Prescribing Patterns. Chest, [S.L.], v. 102, n. 1, p. 270-273, jul. 1992. http://dx.doi.org/10.1378/chest.102.1.270.
ORNSTEIN, Charles et al. We found over 700 doctors who were paid more than a million dollars by drug and medical device companies. ProPublica. 2019. Available: https://www.propublica.org/article/we-found-over-700-doctors-who-were-paid-more-than-a-million-dollars-by-drug-and-medical-device-companies. Accessed on: 11 oct. 2024.
OZIERANSKI, Piotr et al. Exposing drug industry funding of UK patient organisations. Bmj, [S.L.], p. 1-9, 22 may 2019. http://dx.doi.org/10.1136/bmj.l1806.
PEDRIQUE, Belen et al. The drug and vaccine landscape for neglected diseases (2000-11): a systematic assessment. The Lancet Global Health, [S.L.], v. 1, n. 6, p. 371-379, dec. 2013. http://dx.doi.org/10.1016/s2214-109x(13)70078-0.
PHAM‐KANTER, Genevieve. Revisiting Financial Conflicts of Interest in FDA Advisory Committees. The Milbank Quarterly, [S.L.], v. 92, n. 3, p. 446-470, sep. 2014. http://dx.doi.org/10.1111/1468-0009.12073.
PFIZER - Financial Report (2004). New York, NY: Pfizer, 2005. 67 p. Available: https://truecostofhealthcare.org/wp-content/uploads/2015/01/Pfizer_2004.87220720.pdf. Accessed on: 11 oct. 2024.
RAJKUMAR, S. Vincent. The high cost of prescription drugs: causes and solutions. Blood Cancer Journal, [S.L.], v. 10, n. 6, p. 1, 23 jun. 2020. http://dx.doi.org/10.1038/s41408-020-0338-x.
REUTERS - News Agency. Merck Sees Slightly Higher 2007 Earnings. The New York Times. 2006. Available: https://www.nytimes.com/2006/12/07/business/07drug.html. Accessed on: 11 oct. 2024.
ROBBINS, Rebecca. How a Drug Company Made $114 Billion by Gaming the U.S. Patent System. The New York Times. 2023. Available: https://www.nytimes.com/2023/01/28/business/humira-abbvie-monopoly.html. Accessed on: 11 oct. 2024.
SISMONDO, Sergio. Ghost Management: how much of the medical literature is shaped behind the scenes by the pharmaceutical industry?. Plos Medicine, [S.L.], v. 4, n. 9, p. 286, 25 sep. 2007. http://dx.doi.org/10.1371/journal.pmed.0040286.
SISMONDO, Sergio. Pharmaceutical company funding and its consequences: a qualitative systematic review. Contemporary Clinical Trials, [S.L.], v. 29, n. 2, p. 109-113, mar. 2008. http://dx.doi.org/10.1016/j.cct.2007.08.001.
SOMO - investigates multinationals. Public health over pharmaceutical profit. 2024. Available: https://www.somo.nl/our-work/sectors/pharmaceutical-industry/. Accessed on: 11 oct. 2024.
SPIELMANS, Glen I. et al. From Evidence-based Medicine to Marketing-based Medicine: evidence from internal industry documents. Journal of Bioethical Inquiry, [S.L.], v. 7, n. 1, p. 13-29, 21 jan. 2010. http://dx.doi.org/10.1007/s11673-010-9208-8.
STACCIARINI, João Henrique Santana. The Consolidation of the Pharmaceutical Sector in the Global Economy: growth, influence, deviations, and marketing. 2023. 145 p. PhD Thesis - Geography, Universidade Federal de Goiás, Goiânia (Brazil), 2023. https://doi.org/10.5281/zenodo.10377840.
STACCIARINI, João Henrique Santana. Drug advertising in Brazil. Sociedade & Natureza, [S.L.], v. 36, n. 1, p. e72114, 4 jul. 2024c. http://dx.doi.org/10.14393/sn-v36-2024-72114x.
STACCIARINI, João Henrique Santana. O Setor Farmacêutico Global: números e dinâmicas. Caminhos de Geografia, [S.L.], v. 25, n. 101, p. 240, 3 out. 2024a. http://dx.doi.org/10.14393/rcg2510171398.
STACCIARINI, João Henrique Santana. Research and Development (R&D) in the Pharmaceutical Sector. Revista Terceiro Incluído, [S.L.], v. 14, n. 1, p. e14109, 6 ago. 2024b. http://dx.doi.org/10.5216/teri.v14i1.79594.
STATISTA. Revenue of the worldwide pharmaceutical market from 2001 to 2023. 2024. Available: https://www.statista.com/statistics/263102/pharmaceutical-market-worldwide-revenue-since-2001/. Accessed on: 11 oct. 2024.
TABATABAVAKILI, Sahar et al. Financial Conflicts of Interest in Clinical Practice Guidelines: a systematic review. Mayo Clinic Proceedings: Innovations, Quality & Outcomes, [S.L.], v. 5, n. 2, p. 466 - 475, apr. 2021. http://dx.doi.org/10.1016/j.mayocpiqo.2020.09.016.
THOMAS, Katie. Bayer and Johnson & Johnson Settle lawsuits over xarelto, a blood thinner, for $775 million. The New York Times. 2019. Available: https://www.nytimes.com/2019/03/25/health/xarelto-blood-thinner-lawsuit-settlement.html. Accessed on: 11 oct. 2024.
THOMASE, Katie; SCHMIDT, Michael S. Glaxo Agrees to Pay $3 Billion in Fraud Settlement. The New York Times. 2012. Available: https://www.nytimes.com/2012/07/03/business/glaxosmithkline-agrees-to-pay-3-billion-in-fraud-settlement.html. Accessed on: 11 oct. 2024.
TOPOL, Eric J. Failing the Public Health - Rofecoxib, Merck, and the FDA. New England Journal of Medicine, [S.L.], v. 351, n. 17, p. 1707-1709, 21 oct. 2004. http://dx.doi.org/10.1056/nejmp048286.
TORBATI, Yeganeh; O'CONNELL, Jonathan. Pharmaceutical industry likely to shatter its lobbying record as it works to shape Democrats’ spending bill. The Washington Post. Washington, D.C., U.S. nov. 2021. Available: https://www.washingtonpost.com/business/2021/11/05/pharmaceutical-industry-drug-price-lobbying/. Accessed on: 11 oct. 2024.
TROUILLER, Patrice et al. Drug development for neglected diseases: a deficient market and a public-health policy failure. The Lancet, [S.L.], v. 359, n. 9324, p. 2188-2194, jun. 2002. http://dx.doi.org/10.1016/s0140-6736(02)09096-7.
UNITED STATES. Department of Justice (U.S): Civil Division nº 12-842. Glaxosmithkline to plead guilty and pay $3 billion to resolve fraud allegations and failure to report safety data. Washington, D.C., 02 jul. 2012. Available: https://www.justice.gov/opa/pr/glaxosmithkline-plead-guilty-and-pay-3-billion-resolve-fraud-allegations-and-failure-report . Accessed on: 11 oct. 2024.
UNITED STATES. Department Of Justice (U.S): Civil Division nº 10-487. Pharmaceutical Giant AstraZeneca to Pay $520 Million for off label Drug Marketing. Washington, D.C., 27 apr. 2010. Available: https://www.justice.gov/opa/pr/pharmaceutical-giant-astrazeneca-pay-520-million-label-drug-marketing. Accessed on: 11 oct. 2024.
UNITED STATES. Department Of Justice (U.S): Civil Division nº 11-1524. U.S. pharmaceutical company Merck Sharp & Dohme to pay nearly one billion dollars over promotion of Vioxx. Washington, D.C., 22 nov. 2011. Available: https://www.justice.gov/opa/pr/us-pharmaceutical-company-merck-sharp-dohme-pay-nearly-one-billion-dollars-over-promotion. Accessed on: 11 oct. 2024.
VAN LUIJN, Johan C. F. et al. Superior efficacy of new medicines? European Journal of Clinical Pharmacology, [S.L.], v. 66, n. 5, p. 445-448, mar. 2010. http://dx.doi.org/10.1007/s00228-010-0808-3.
WAZANA, Ashley. Physicians and the Pharmaceutical Industry. Jama, [S.L.], v. 283, n. 3, p. 373, 19 jan. 2000. http://dx.doi.org/10.1001/jama.283.3.373.
WIESELER, Beate et al. New drugs: where did we go wrong and what can we do better?. Bmj, [S.L.], p. 4340, 10 jul. 2019. http://dx.doi.org/10.1136/bmj.l4340.
YEH, James S. et al. Association of Industry Payments to Physicians with the Prescribing of Brand-name Statins in Massachusetts. Jama Internal Medicine, [S.L.], v. 176, n. 6, p. 763, 1 jun. 2016. http://dx.doi.org/10.1001/jamainternmed.2016.1709.
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2024 João Henrique Santana Stacciarini
Esta obra está bajo una licencia internacional Creative Commons Atribución-CompartirIgual 4.0.
